AVITA Medical is a publicly listed (NASDAQ: RCEL, ASX:AVH) regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics’ patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
Location: United States, California, Santa Clarita
Employees: 51-200
Total raised: $159.1M
Founded date: 2008
Investors 1
| Date | Name | Website |
| 25.10.2023 | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.10.2023 | - | $90M | OrbiMed |
| 24.02.2021 | - | $69.1M | - |
Mentions in press and media 20
| Date | Title | Description |
| 08.01.2025 | AVITA Medical’s shares sink 19% after another forecast cut | By Nikita Maria Jino Jan 8 (Reuters) - AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters an... |
| 12.03.2024 | Global Skin Grafting Device Market Size to Surpass US$ 1,519.0 Million by 2030 | Exhibiting a CAGR of 7.1% | Global Skin Grafting Device Market size is expected to reach US$ 1,519.0 Million by 2030, from US$ 942.3 Million in 2023, at a CAGR of 7.1% during the forecast period.” — CoherentMIBURLINGAME, CA 94010, UNITED STATES, March 12, 2024 /EINPre... |
| 19.10.2023 | AVITA Medical Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives | - |
| 18.10.2023 | AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives | - |
| 26.06.2023 | AVITA Medical Rejoins the Russell 3000 Index | /EIN News/ -- VALENCIA, Calif., and MELBOURNE, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class device... |
| 16.06.2023 | AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients | /EIN News/ -- VALENCIA, Calif. and MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices... |
| 15.06.2023 | AVITA Medical Announces Appointment of David O’Toole as Chief Financial Officer | /EIN News/ -- VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices... |
| 08.06.2023 | AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects | /EIN News/ -- VALENCIA, Calif. and MELBOURNE, Australia, June 07, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices... |
| 15.05.2023 | AVITA Medical to Host Investor Webinar Briefing | /EIN News/ -- VALENCIA, Calif. and MELBOURNE, Australia, May 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices ... |
| 11.05.2023 | AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance | /EIN News/ -- VALENCIA, Calif. and MELBOURNE, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-i... |
Show more